REG - Hikma Pharmaceutical - Director/PDMR Shareholding
25/02/2022 09:45
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220225:nRSY8472Ca&default-theme=true
RNS Number : 8472C Hikma Pharmaceuticals Plc 25 February 2022
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 25 February 2022: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai:
HIK)
(LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the
following conditional awards under the Hikma Pharmaceuticals PLC 2014
Executive Incentive Plan (the "EIP") to Persons Discharging Managerial
Responsibility ("PDMR") of the Company.
Awards under the EIP were made on 25 February 2022 at a price of 2,219 pence
per Ordinary Share (being the average price for the 30-day period prior to 31
December 2021, in accordance with the EIP rules) as follows:
Notification and public disclosure of transactions by persons discharging
managerial responsibilities
Said Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 34,652
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Said Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 18,420
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Sigurdur Olafsson
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Sigurdur Olafsson
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 42,672
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Sigurdur Olafsson
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Sigurdur Olafsson
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 23,938
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Mazen Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 27,764
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Mazen Darwazah
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 15,524
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Bassam Kanaan
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Bassam Kanaan
2 Reason for the notification
a) Position/status EVP, Corporate Development and M&A
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 20,588
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Bassam Kanaan
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Bassam Kanaan
2 Reason for the notification
a) Position/status EVP, Corporate Development and M&A
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 16,472
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Khalid Nabilsi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Khalid Nabilsi
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 20,643
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Khalid Nabilsi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Khalid Nabilsi
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 17,003
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Riad Mishlawi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Riad Mishlawi
2 Reason for the notification
a) Position/status President, Injectables
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 22,099
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Riad Mishlawi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Riad Mishlawi
2 Reason for the notification
a) Position/status President, Injectables
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 18,691
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Majda Labadi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Majda Labadi
2 Reason for the notification
a) Position/status EVP, Organisational Development
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 13,511
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Majda Labadi
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Majda Labadi
2 Reason for the notification
a) Position/status EVP, Organisational Development
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 10,778
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Susan Ringdal
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Susan Ringdal
2 Reason for the notification
a) Position/status EVP, Strategic Planning and Global Affairs
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 11,072
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Susan Ringdal
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Susan Ringdal
2 Reason for the notification
a) Position/status EVP, Strategic Planning and Global Affairs
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 8,851
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Brian Hoffmann
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Brian Hoffmann
2 Reason for the notification
a) Position/status President, US Generics
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 14,663
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Brian Hoffmann
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Brian Hoffmann
2 Reason for the notification
a) Position/status President, US Generics
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 12,405
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Henriette Nielsen
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Henriette Nielsen
2 Reason for the notification
a) Position/status EVP, Business Operations
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 16,610
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Henriette Nielsen
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Henriette Nielsen
2 Reason for the notification
a) Position/status EVP, Business Operations
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 13,423
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Shahin Fesharaki
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Shahin Fesharaki
2 Reason for the notification
a) Position/status Chief Scientific Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 18,092
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Shahin Fesharaki
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Shahin Fesharaki
2 Reason for the notification
a) Position/status Chief Scientific Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 14,424
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Hussein Arkhagha
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Hussein Arkhagha
2 Reason for the notification
a) Position/status Chief Counsel
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element B of the 2014 Executive Incentive Plan (EIP). Shares
under Element B EIP award will vest after 2 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 10,598
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Hussein Arkhagha
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Hussein Arkhagha
2 Reason for the notification
a) Position/status Chief Counsel
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification Description: Ordinary shares of 10 pence each (Shares)
code
ID Code: GB00B0LCW083
b) Nature of the transaction The Company granted the named individual above a conditional award to acquire
Shares under Element C of the 2014 Executive Incentive Plan (EIP). Shares
under Element C EIP award will vest after 3 years.
c) Price(s) and volume(s) Price(s): £22.19
Volume(s): 8,675
d) Aggregated information N/A
e) Date of the transaction 25 February 2022
f) Place of the transaction London Stock Exchange (XLON)
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHGCGDDXXDDGDURecent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Result of AGM
AnnouncementREG - Hikma Pharmaceutical - Trading Statement
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Hikma appoints new President of Generics business
AnnouncementREG - Hikma Pharmaceutical - Director/PDMR Shareholding
Announcement